Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation
JAMA Neurol
.
2016 Nov 1;73(11):1375.
doi: 10.1001/jamaneurol.2016.3199.
Authors
Martin Merschhemke
1
,
Davorka Tomic
1
,
Norman Putzki
1
Affiliation
1
Novartis Pharma AG, Basel, Switzerland.
PMID:
27669336
DOI:
10.1001/jamaneurol.2016.3199
No abstract available
Publication types
Letter
Comment
MeSH terms
Fingolimod Hydrochloride*
Humans
Immunosuppressive Agents
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting
Substances
Immunosuppressive Agents
Fingolimod Hydrochloride